© 2020 MJH Life Sciences and Urology Times. All rights reserved.
Prostate Cancer
How to code for a perineal prostate biopsy
June 15, 2020
Three codes are available for prostate biopsy, but only one is typically used for perineal biopsy, according to Jonathan Rubenstein, MD, and Mark Painter.
Prostate Ca assay appears similarly predictive of adverse pathology in African American, Caucasian patients
June 15, 2020
In this video, Eric Klein, MD, discusses a study evaluating the 17-gene Oncotype DX Genomic Prostate Score assay in African American and Caucasian American men.
Research confirms prognostic performance of genomic classifier
June 10, 2020
The classifier can be a useful adjunct for clinical decision-making, an investigator says.
Enzalutamide reduces risk of death in men with nmCRPC by 27% vs placebo
June 01, 2020
This final analysis of the phase 3 PROSPER study supports enzalutamide and androgen deprivation therapy as the standard of care to improve overall survival in prostate cancer patients before the onset of detectable metastasis.
Apalutamide plus ADT improves OS in men with non-metastatic castration-resistant PCa
June 01, 2020
Apalutamide (ERLEADA) combined with androgen deprivation therapy improves overall survival more than androgen deprivation therapy alone in men with non-metastatic castration-resistant prostate cancer at high risk of metastases, according to results from investigators’ final analysis of the phase 3 SPARTAN trial.
Robotics in GU oncology: Current status, future directions
May 22, 2020
The breadth of applications will widen as the number of new platforms grows, according Joshua Calvert, MD, MPH.
FDA approves 2 PARP inhibitors for certain men with prostate cancer
May 21, 2020
The FDA has approved 2 poly (ADP-ribose) polymerase (PARP) inhibitors for men with metastatic castration-resistant prostate cancer who have certain genetic mutations, marking the first approvals of this newer drug class in prostate cancer.
PD-1 inhibitor shows some antitumor activity in prostate cancer
May 18, 2020
With additional follow-up of approximately 10 months, monotherapy with the PD-1 inhibitor pembrolizumab (Keytruda) continued to show antitumor activity in men with metastatic castration-resistant prostate cancer. However, monotherapy alone is likely not a sufficient treatment in this patient population, according to Emmanuel Antonarakis, MBBCh, professor of oncology at Johns Hopkins University in Baltimore, Maryland.
Data reveal prevalence of advanced prostate cancer states
May 18, 2020
Findings from a systematic literature review further our understanding of the prevalence of distinct clinical states of advanced prostate cancer, their association with homologous recombination repair (HRR) gene alterations, and the use of testing methods to identify HRR gene alterations, researchers say.
Pre-chemo radium-223 does not affect chemo regimens
May 08, 2020
In a recent study, researchers examined real-world outcomes for patients with metastatic castration-resistant prostate cancer treated with radium-223 (Xofigo). Study author Rana R. McKay, MD, of UC San Diego Health, discusses this study and its significance in the castration-resistant prostate cancer landscape.